A hypoallergenic claim reads like a promise about the customer. A repeat insult patch test produces something narrower: a result about a group of volunteers, under a defined protocol, on one formula, at one point in time. The gap between those two is where brands get into trouble, & it is not usually closed by buying more testing. It is closed by writing copy that says what the study actually showed.
This article sets out what this kind of panel study measures, how the phases work, what a result supports in marketing wording, which words stay off a label, why hypoallergenic is not a free word, how expectations differ between markets, & which documents a brand should hold before & after the work. It is written for the buyer commissioning or reviewing the study, not for the clinic running it. It does not set out legal requirements for any market; what a claim requires, the protocol expected & the wording permitted differ by destination & change over time, so the position should be confirmed from the official text for each market & with a qualified professional before copy is printed. The wording limits on a gentle positioning are set out in our sensitive skin wording guide, & the wider claim review is covered in our article on anti-ageing wording.
What a repeat insult patch test measures
A repeat insult patch test is a human skin compatibility study run on volunteers under occlusion. The product, or a dilution of it, is applied to the same site repeatedly over a period, & the site is read by a trained assessor. The purpose is to observe whether repeated contact produces a response over the course of the study, & then whether a later single contact produces one after a rest period.
It is a compatibility study, not an efficacy study. It says nothing about whether the product does anything for the skin, & it says nothing about how the product performs. A brand that buys one to support a performance story has bought the wrong instrument, & the mismatch is visible to a reviewer.
It is also a study about one formula. The result belongs to the batch submitted, made to the specification in force at the time. A later change to a raw material, to a supplier, to a fragrance level or to a preservative can move the result, which is why the formula version has to be recorded alongside the report.
The induction phase, the challenge phase
The study has two parts. In the induction phase, the material is applied to the same site on a repeated schedule, & the site is read before each application. The readings during this phase show how the skin responds to repeated contact under occlusion, which is a harsher condition than normal use.
Between the two parts there is a rest period, long enough for any response from the induction phase to settle. The challenge phase then applies the material once more, to the original site & often to a fresh one, & the site is read again after a defined interval. The point of the second application is to see whether the earlier contact changed how the skin responds.
The readings in both phases are graded by a trained assessor against a scale, & the grading is the output. A brand should ask what scale was used, who did the grading, & whether the same person read the site throughout, because a change of reader part way through a study introduces a variable the report cannot remove afterwards.
Who sits on a panel, why the panel matters
The panel is the study. Its size, its composition & the way volunteers were recruited decide how much weight the result carries, & a report that does not describe the panel in detail is a report a reviewer will question first.
The brand should ask how the panel was selected, whether anyone with a relevant history was excluded, & how many volunteers completed the study rather than started it. Completion matters more than recruitment, because a volunteer who withdraws part way through is a data point that has to be handled, & the way it was handled should be stated rather than assumed.
The brand should also ask whether the panel was recruited for this product or drawn from a standing pool. A standing pool is common & perfectly acceptable, but it means the same volunteers appear across a number of studies, & a reviewer who knows the field may ask about it. The honest answer is to state the arrangement in the protocol rather than to leave it to be found.
What a passing result actually supports
A result supports a statement about the study, & through it a modest statement about the product. It supports saying that the product was assessed on human skin under a defined protocol, & that the outcome was as reported. That is a real & useful statement, & it is the one most brands should use.
It does not support a promise. No routine panel study establishes that a product will not produce a response in any individual, because individual responses vary & no panel represents every person who will ever buy the product. A claim written as though the study delivered that guarantee is a claim the study does not carry.
It also does not support a comparison. A result on one formula does not establish that the product is gentler than another one, unless the study was designed as a comparison & run that way. A comparative claim is a separate piece of work with its own protocol, & it should be commissioned as one rather than inferred from two unrelated studies.
Wording the result allows in copy
The safest wording describes the assessment rather than the outcome. A phrase that says the product was tested on human skin under a defined protocol, with the result available, is verifiable from the report & survives review because there is a document behind every word in it.
The next safest describes the composition. A statement about what was left out, about the fragrance position, or about the base being chosen for a sensitive positioning is verifiable from the formula sheet, & it does not depend on a study at all. Many brands find that this wording does more commercial work than a claim about testing.
Where a brand does want to refer to the study in copy, the reference should be accurate about what was done. Naming the study type, the panel & the outcome, without stretching the outcome into a promise, keeps the copy inside the evidence. A qualified professional should read the intended sentence against the report & against the rules of each destination market before it is printed.
Wording that stays off the label
Absolute promises stay off. No reaction, will not irritate, safe for everyone, & suitable for all skin types are each statements no study can support, & each one invites a question the brand cannot answer. The commercial idea behind them can usually be expressed as a composition statement instead.
Medical-sounding wording stays off. A cosmetic product is not a medicinal product, & a phrase that points at a condition, at a symptom, or at the body's structure or function takes the product outside the cosmetic category in most jurisdictions. That is a far larger problem than a wording correction, because it changes the regulatory status of the product rather than the copy.
Wording borrowed from a supplier stays off. A raw material supplier's data describes the material, not the finished product, & it was written for a different purpose. Repeating it as the brand's own claim moves the substantiation duty onto the brand without moving the evidence with it.
Hypoallergenic: why the word is not free
Hypoallergenic is not a description of a test result. It is a claim about the product, & markets differ on what has to sit behind it before it may be used. Some expect a defined study, some expect a reasoned assessment, & some read the word as implying more than any single study can deliver.
That variation is the reason to regard the word as a decision rather than a decoration. A brand selling in more than one market should check the position in each, & should expect the stricter position to be the one a retailer or a marketplace applies. The applicable requirement, & the evidence expected, should be confirmed from the official text & with a qualified professional rather than assumed from a previous launch.
The commercial trap is that the word is short, familiar & effective on a pack. A brand that prints it because it reads well, & discovers afterwards that its market expects a specific study, has a relabel to run against a fixed launch date. The check costs far less before artwork than after it.
Market differences in what is expected
Expectations differ on three things: whether a human study is expected at all, what protocol is regarded as appropriate, & how the result may be described in copy. A claim that is unremarkable in one destination can be outside the rules in another, & the difference is not always obvious from the outside.
The practical approach is to fix the wording per market rather than to write one global sentence. Copy that travels is usually copy that describes composition & assessment rather than copy that promises an outcome, because the descriptive version tends to sit inside more rule sets than the promissory one.
Expectations also move. Protocols are revised, guidance is updated, & a claim position that held at one launch may not hold at the next. A brand should regard each claim as a decision made for a market at a time, & should re-check it at each relaunch rather than carrying it forward on the strength of the last review.
The documents a brand should hold
Before the study, the file should hold the formula with its version, the specification for the batch submitted, the safety documentation for the finished product, & the protocol. The protocol is the important one, because it is what a reviewer reads to judge whether the study was designed to answer the question the brand is now asking.
The file should also hold the sample identification. Which batch was submitted, when it was made, how it was transported, & how it was stored at the clinic all belong in the record, because a study on a sample that degraded in transit is a study about a degraded sample. This is ordinary record keeping & it is rarely contested.
Finally the file should hold the intended copy. The wording the brand wants to use is what the study has to support, so it should be written down before the work is commissioned rather than chosen afterwards. A study designed without the wording in mind frequently cannot support the sentence the brand eventually wants.
After the study, the file should hold the full report rather than a summary letter. A one-page letter stating that the product passed is not sufficient evidence for a claim, because it does not show the panel, the grading scale, the readings or the withdrawals. The report is the evidence; the letter is a notification that evidence exists.
It should hold the qualifications of whoever reviewed the result. A raw set of readings is not a conclusion, & the step from readings to a claim is a professional judgement. That judgement should be written down, signed, & dated, & it should name the wording it supports.
It should also hold a change log. Anything that changes the formula, the supplier of a critical material, or the fragrance level after the study is a reason to consider whether the result still applies. A brand that can show the log can show that the result was still true at the time the claim was made.
Retesting: when a result stops being true
A result stops being true when the product stops being the same product. A reformulation is the obvious case, & the less obvious ones catch brands out: a supplier change for a surfactant, a change of fragrance level, a preservative adjustment made to solve a stability problem, or a different botanical grade after a poor harvest.
The second trigger is a change of pack or of use pattern. A product reformulated for a leave-on application was not studied as a rinse-off one, & a study on a product applied to the arm does not automatically cover a product used around the eyes. The intended use belongs in the protocol, & a change of intended use is a new question.
The practical control is a written rule rather than a judgement call. A brand should decide in advance which changes trigger a fresh look at the claim, who decides, & what happens to stock already printed. A rule agreed before the first launch is far easier to apply than one invented during a reformulation.
Claim evidence at a glance
The table below sets each kind of evidence against what it measures, what it can support in copy, & the point that is easy to miss. The rows are a working comparison rather than a statement of what any market requires: which evidence a claim needs, & how it may be described, differ by destination & change over time, so confirm the position from the official text for each market & with a qualified professional before printing any wording.
| Evidence | What it measures | What it can support in copy | Easy to miss |
|---|---|---|---|
| Repeat insult patch study | Response to repeated contact under occlusion | A statement about the assessment itself | The result belongs to one formula version |
| Single application patch study | Response to one contact | A limited statement about one exposure | Does not address repeated use |
| Expert review of the formula | A professional reading of the composition | A composition-led positioning | Not a substitute for a study where one is expected |
| In-use home assessment | Response under real use conditions | A statement about use as directed | Reporting depends on the participant |
| Stability, compatibility data | Whether the product holds up over time | Nothing about skin response directly | Sometimes filed as though it were skin evidence |
| Raw material literature | What is known about an ingredient | Nothing on its own about the product | Describes the material, not the formulation |
| Signed claim review | Whether the wording matches the evidence | The wording it names, & nothing more | A review without a date & a scope is weak |
The rows are a starting map rather than a rule. A brand that writes the intended wording before commissioning anything gets evidence that fits the sentence; a brand that commissions first & writes afterwards gets a report that supports a sentence it did not want, & the gap is discovered at artwork approval.
What to put in the brief
Write the wording you want before you commission the work, because the wording sets the protocol. Name the markets, since the evidence expected & the way it may be described are not the same everywhere. Then name who will hold the report, & for how long, because the file has to outlast the launch rather than the project.
- The exact wording you intend to print, & the markets it will appear in.
- The formula version, & the specification of the batch you will submit.
- The intended use pattern: rinse-off or leave-on, area of application, frequency.
- Whether a human study is expected in your market, & by whom that is judged.
- Whether the protocol will be shown to you before the study starts.
- Who will review the result, & whether the review will be written & signed.
- Which future formulation changes will trigger a fresh look at the claim.
- Who holds the report, & how it reaches the person writing the copy.
Then agree what happens on a change. The useful arrangement is a named owner for the claim, a written rule on which changes force a re-review, & a dated record each time the wording is re-approved, so the file shows the decision rather than the intention.
Where our capability fits
We ask which wording a brand intends before any compatibility work is discussed, because the wording sets the protocol & the protocol is expensive to redo. We hold the formula version & the specification of the batch submitted alongside the report, we tell the brand which future changes would put the claim in question, & we say plainly where a study result does not reach the sentence the marketing team wants rather than letting the gap surface at artwork approval.
We work with brands on private label (your brand on a proven base), OEM/ODM contract manufacturing & full custom formula development, & the claim position is agreed at the brief rather than after the first run. Our lines include a centella gentle cleanser tube, a pale green calming serum capsule & a moisturising face cream in a glass jar, each developed with the wording & the supporting documents recorded together.
Tell us the claim you have in mind, the markets you sell in, & the base you are working from, & we will come back with what the evidence can support, which documents we need to hold, & where a professional opinion is required before print. Start at our inquiry page, email capsulebiotech@163.com, or message the right team on WhatsApp: Capsule Series (capsules only) +86 158-7655-5319, Cosmetics Series (serum, hair care, body care, fragrance) +86 158-7655-5319.
General manufacturing information, not regulatory or legal advice. What a claim requires, the study design expected, how a result may be described in copy & the evidence a market will accept differ by destination, by product category & over time, & the applicable position should be confirmed from the official text for each market & with a qualified professional before a product is placed on sale.